1 of 1
Story summary
- Insilico Medicine has nominated ISM6200, an NR3C1 inhibitor, for platinum-resistant ovarian cancer and cortisol-related conditions.
- The candidate shows potential for lower drug-drug interaction risks and effective treatment at reduced doses.
- Preclinical studies indicate significant anti-tumor efficacy when ISM6200 is combined with paclitaxel.
- Zentalis Pharmaceuticals has selected a 400 mg dose of azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer after positive interim trial results.
